How does Burna AI compare to Flatiron Health as a business model?

Flatiron captured oncology real-world evidence from EHRs and sold the resulting dataset and analytics to pharma. Flatiron was pre-AI and single-sided: it served the data buyer (pharma), not the data producer (the oncologist), and was acquired by Roche for $1.9 billion in 2018. Burna AI is AI-native and two-sided. Provider SaaS at cancer centers and CROs (the data producer); Protocol Safe and Postmarket Pharmacovigilance at pharma (the data buyer); the data quality layer is the company; the product is the proof you can build the layer. Same Flatiron structural insight, applied to higher-stakes data (safety, not just outcomes) with native AI architecture and a substantially larger TAM across the drug lifecycle.